Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 353-361, September 2009

CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116

  • Claudia Dittfeld

      Affiliations

    • Tumor Pathophysiology, OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Germany
    • Contributed equally.
  • ,
  • Antje Dietrich

      Affiliations

    • Tumor Pathophysiology, OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Germany
    • Contributed equally.
  • ,
  • Susann Peickert

      Affiliations

    • Tumor Pathophysiology, OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Germany
  • ,
  • Sandra Hering

      Affiliations

    • Institute of Legal Medicine, Dresden University of Technology, Germany
  • ,
  • Michael Baumann

      Affiliations

    • OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Germany
    • Department of Radiation Oncology, University Hospital Dresden, Germany
  • ,
  • Marian Grade

      Affiliations

    • Department of General and Visceral Surgery, University Medicine Goettingen, Germany
  • ,
  • Thomas Ried

      Affiliations

    • National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
  • ,
  • Leoni A. Kunz-Schughart

      Affiliations

    • Tumor Pathophysiology, OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Germany
    • Corresponding Author InformationCorresponding author. Address: OncoRay – Center for Radiation Research in Oncology, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Fetscherstraße 74, PF 86, 01307 Dresden, Germany.

Received 28 April 2009; received in revised form 17 June 2009; accepted 24 June 2009. published online 25 August 2009.

Abstract 

Background and purpose

CD133 is controversially discussed as putative (surrogate) marker for cancer stem/tumor-initiating cell populations (CSC/TIC) in epithelial tumors including colorectal carcinomas (CRCs). We studied CD133 expression in established CRC cell lines and examined in vitro behavior, radioresponse and in vivo tumor formation of CD133+/− subpopulations of one cell line of interest.

Materials and methods

Ten CRC cell lines were analyzed for CD133 expression using flow cytometry and Western blotting. CD133+ and CD133 HCT-116 subpopulations were separated by FACS and studied in 2-D and 3-D culture and colony formation assays after irradiation. Subcutaneous xenograft formation was monitored in NMRI (nu/nu) mice.

Results and conclusions

CRC cell lines could be classified into three groups: (i) CD133, (ii) CD133+ and (iii) those with two distinct CD133+ and CD133 subpopulations. Isolated CD133+/− HCT-116 subpopulations were studied relative to the original fraction. No difference was found in 2-D growth, spheroid formation or radioresponse in vitro. Also, tumor formation and growth rate did not differ for the sorted subpopulations. However, a subset of xenografts originated from CD133 HCT-116 showed a striking enrichment in the CD133+ fraction. Our data show that CD133 expression is not selective for sphere forming, tumor-initiating or radioresistant subpopulations in the HCT-116 CRC cell lines. This implies that CD133 cannot be regarded as a CSC/TIC marker in all CRC cell lines and that functional measurements of tumor formation have to generally accompany CSC/TIC-directed mechanistic or therapeutic studies.

Keywords: Cancer stem/tumor-initiating cells (CSC/TIC), Colorectal carcinoma (CRC) cell lines, HCT-116, 2-D culture, 3-D culture, Radioresponse

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(09)00338-7

doi:10.1016/j.radonc.2009.06.034

Refers to erratum:

  • CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116 , 18 November 2009

    Claudia Dittfeld, Antje Dietrich, Susann Peickert, Sandra Hering, Michael Baumann, Marian Grade, Thomas Ried, Leoni A. Kunz-Schughart
    Radiotherapy & Oncology March 2010 (Vol. 94, Issue 3, Pages 375-383)

Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 353-361, September 2009